Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Mak

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Reproductive Biomedicine Online|December 10, 2002
Mechanisms of decidualizationMark Christian, Ian Mak, John O White, et al.
Fertility and Sterility|October 10, 2002
Aromatase P450 messenger RNA expression in eutopic endometrium is not a specific marker for pelvic endometriosisKavitha Dheenadayalu, Ian Mak, Stephan Gordts, et al.
Prosthetics and Orthotics International|June 24, 2008
The effect of time on qualitative compliance in brace treatment for AISIan Mak, Edmond Lou, James V Raso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2006
Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinomaChooi P Lee, Poulam M Patel, Peter J Selby, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Reproductive Biomedicine Online|December 10, 2002
Mechanisms of decidualizationMark Christian, Ian Mak, John O White, et al.
Fertility and Sterility|October 10, 2002
Aromatase P450 messenger RNA expression in eutopic endometrium is not a specific marker for pelvic endometriosisKavitha Dheenadayalu, Ian Mak, Stephan Gordts, et al.
Prosthetics and Orthotics International|June 24, 2008
The effect of time on qualitative compliance in brace treatment for AISIan Mak, Edmond Lou, James V Raso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2006
Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinomaChooi P Lee, Poulam M Patel, Peter J Selby, et al.
Pageof 1